Ngā hua rapu - Daniel Tenney
- E whakaatu ana i te 1 - 1 hua o te 1
-
1
Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915 mā James Larkin, Jeffrey Weber, Georgina V Long, Jonathan Baden, Hao Tang, Corey Ritchings, Michele Del Vecchio, Keyur Desai, Daniel Tenney, Han Chang, Gina Fusaro, David Balli, Sonia Dolfi, Sheen Wang, Shu-Pang Huang
I whakaputaina 2025-07-01Purpose CheckMate 915 (NCT03068455) compared adjuvant nivolumab monotherapy versus combination nivolumab+ipilimumab in patients with resected stage III/IV melanoma. This exploratory analysis was performed to identify biomarkers that correlate with benefit from adjuvant immunotherapy.Patients and met...
Whiwhi kuputuhi katoa
Tuhinga